(1) 62 Depressed patients were observed in a double blind study.
(2) There was a 60% general improvement in the drug treated group.
Comparison of the drug and control group by clinical evaluation was significant at the 1% level of confidence.
(3) The differences between a small number (35) of drug and control patients were not significant in the psychological tests employed.
(4) The drug may have some E.C.T. sparing effect.
(5) No serious complications or side effects were encountered
References
1.
KuhnR.Uber die Behandlung depressiver Zustande mit einem Iminodibenzylderivat (G22355).Schw. Med. Wchnschr.35/36, 1135–1140, August 31, 1957.
2.
LehmannH. E., CahnC. H., and deVerteuilR. L.The treatment of depressive conditions with Imipramine (G22355).Canad. Psychiat. Assoc. J.3, 155–164, October, 1958.
3.
AzimaH.Imipramine (Tofranil) A new drug for the depressed.Canad. Med. Assoc. J.80, 535–540, April, 1959.
4.
MannA. N., and McPhersonA. S.Clinical experience with Imipramine in the treatment of depression.Canad. Psychiat. Assoc. J.4, 38–47. January, 1959.
5.
AzimaH., and VispoR. H.Imipramine — A potent new anti-depressant compound.Am. J. Psychiat.115, 245–6, September, 1958.
